Precision medicine for metastatic breast cancer—limitations and solutions

[1]  Setia Pramana,et al.  Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival , 2015, Bioinform..

[2]  E. Winer,et al.  Abstract CT231: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2-, advanced/metastatic breast cancer , 2015 .

[3]  C. Desmedt,et al.  Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Ryan,et al.  ATM and ATR as therapeutic targets in cancer. , 2015, Pharmacology & therapeutics.

[5]  S. Gabriel,et al.  Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 , 2015 .

[6]  E. Winer,et al.  Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients withPIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer , 2015 .

[7]  L. Pusztai,et al.  Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer , 2015 .

[8]  Michael P. Schroeder,et al.  In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. , 2015, Cancer cell.

[9]  C. Massard.  O3.7Enriching phase I trials with molecular alterations: Interim analysis of 708 patients enrolled in the MOSCATO 01 , 2015 .

[10]  H Abe,et al.  Emergence of resistant variants detected by ultra‐deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1 , 2015, Journal of viral hepatitis.

[11]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Sohrab P. Shah,et al.  Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution , 2014, Nature.

[13]  J. Baselga,et al.  Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Paules,et al.  Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents , 2014, Cell cycle.

[15]  S. Loibl,et al.  Does toxicity predict efficacy? Insight into the mechanism of action of lapatinib. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[17]  Obi L. Griffith,et al.  Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor , 2014, Nature.

[18]  C Sotiriou,et al.  The AURORA initiative for metastatic breast cancer , 2014, British Journal of Cancer.

[19]  M. Berger,et al.  Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  S. Loi,et al.  351OGENOMIC AND IMMUNE CHARACTERIZATION OF METASTATIC BREAST CANCER (MBC): AND ANCILLARY STUDY OF THE SAFIR01 & MOSCATO TRIALS. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  M. Kris,et al.  LBA39_PRNERATINIB (N) WITH OR WITHOUT TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING HER2 SOMATIC MUTATIONS: AN INTERNATIONAL RANDOMIZED PHASE II STUDY , 2014 .

[22]  Sridhar Ramaswamy,et al.  Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility , 2014, Science.

[23]  N. Navin,et al.  Clonal Evolution in Breast Cancer Revealed by Single Nucleus Genome Sequencing , 2014, Nature.

[24]  A. Schneeweiss,et al.  Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study , 2014, Breast Cancer Research.

[25]  S. Henderson,et al.  APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. , 2014, Cell reports.

[26]  A. Tutt,et al.  Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers , 2014, Breast Cancer Research.

[27]  M. Zucchetti,et al.  Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  J. Blay,et al.  VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). , 2014 .

[29]  C. Isaacs,et al.  Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Oncology.

[30]  A. D. Van den Abbeele,et al.  Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Erdmann,et al.  Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials , 2014, Molecular Cancer Therapeutics.

[32]  Thomas Bachelot,et al.  Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). , 2014, The Lancet. Oncology.

[33]  M. Dowsett,et al.  Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[35]  Adam Kiezun,et al.  Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine , 2013, Nature Medicine.

[36]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[37]  Javed Siddiqui,et al.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.

[38]  N. Rosen,et al.  Tumor adaptation and resistance to RAF inhibitors , 2013, Nature Medicine.

[39]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[40]  Alan Ashworth,et al.  Mechanisms of resistance to therapies targeting BRCA-mutant cancers , 2013, Nature Medicine.

[41]  Mark J. Ratain,et al.  Tumour heterogeneity in the clinic , 2013, Nature.

[42]  Michael P. Schroeder,et al.  IntOGen-mutations identifies cancer drivers across tumor types , 2013, Nature Methods.

[43]  X. Hua,et al.  DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies. , 2013, American journal of human genetics.

[44]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[45]  R. Salunga,et al.  Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. , 2013, Annals of diagnostic pathology.

[46]  Jinglong Wang,et al.  Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer , 2013, Molecular Cancer Research.

[47]  G. Hortobagyi,et al.  Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2. , 2013 .

[48]  Thomas Bachelot,et al.  Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer , 2013, Clinical Cancer Research.

[49]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[50]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[51]  Li Ding,et al.  Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.

[52]  John M. S. Bartlett,et al.  PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer , 2013, PloS one.

[53]  M. Mathieu,et al.  Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. , 2012, European journal of cancer.

[54]  Matthew B. Callaway,et al.  MuSiC: Identifying mutational significance in cancer genomes , 2012, Genome research.

[55]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[56]  H. Gómez,et al.  A gene expression signature of MEK pathway activation to predict survival in triple-negative breast cancer. , 2012 .

[57]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[58]  L. Zitvogel,et al.  Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer , 2012, Oncoimmunology.

[59]  Stefan Michiels,et al.  Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[61]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[62]  Razelle Kurzrock,et al.  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Mark Clemons,et al.  Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Jordi Rodon,et al.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  J. Baselga,et al.  A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors , 2011, Clinical Cancer Research.

[66]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[67]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[68]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[69]  Young Lim Choi,et al.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.

[70]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[71]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[72]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[73]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[74]  C. Sander,et al.  Functional Copy-Number Alterations in Cancer , 2008, PloS one.

[75]  L. Pusztai,et al.  Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[77]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[78]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[79]  R. Tampé,et al.  Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. , 2001, Cancer research.

[80]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[81]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[82]  E. Jensen,et al.  Estrogen-Receptor Interaction , 1973, Science.

[83]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[84]  J. Wolchok,et al.  Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. , 2015, The New England journal of medicine.

[85]  D. Spaeth,et al.  Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. , 2015, Annals of Oncology.

[86]  G. Prendergast.  A perspective on cancer as an abortive autoimmune response to altered-self. , 2015, Cancer research.

[87]  Dennis C. Friedrich,et al.  Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .

[88]  G. Hortobagyi,et al.  Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[90]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[91]  Daniel F. Hayes,et al.  Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer , 2013 .

[92]  G. Hortobagyi,et al.  Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  J. Thigpen.  Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer , 2012 .

[94]  K. Gelmon,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[95]  G. Hortobagyi,et al.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[97]  C. Osborne,et al.  Tamoxifen in the treatment of breast cancer. , 1998, The New England journal of medicine.